2010
The treatment of moderate-to-severe psoriasis: prescreening and monitoring psoriatic patients on biologics.
Levine D, Strober B. The treatment of moderate-to-severe psoriasis: prescreening and monitoring psoriatic patients on biologics. Seminars In Cutaneous Medicine And Surgery 2010, 29: 28-34. PMID: 20430305, DOI: 10.1016/j.sder.2010.02.003.Peer-Reviewed Original ResearchConceptsSevere psoriasisUS FoodDrug AdministrationTumor necrosis factor-alpha inhibitorsNecrosis factor-alpha inhibitorsInterleukin-12/23 inhibitorsShort-term safetyT-cell modulatorDevelopment of biologicsBiologic therapyPsoriasis patientsPsoriatic patientsClinical trialsTherapeutic monitoringSpecific patientPatientsBiologicsMedicationsPsoriasisLong-term dataAdministrationTreatmentCurrent bodyInhibitorsEvidence
2009
Psoriasis in patients with HIV infection: From the Medical Board of the National Psoriasis Foundation
Menon K, Van Voorhees A, Bebo B, Gladman D, Hsu S, Kalb R, Lebwohl M, Strober B, Foundation P. Psoriasis in patients with HIV infection: From the Medical Board of the National Psoriasis Foundation. Journal Of The American Academy Of Dermatology 2009, 62: 291-299. PMID: 19646777, DOI: 10.1016/j.jaad.2009.03.047.Peer-Reviewed Original ResearchConceptsHuman immunodeficiency virusHIV-associated psoriasisPotential adverse eventsPsoriatic arthritisAdverse eventsHIV infectionSevere diseaseTumor necrosis factor-alpha inhibitorsNecrosis factor-alpha inhibitorsNational Psoriasis Foundation Medical BoardFirst-line therapeutic agentsPlacebo-controlled trialSecond-line treatmentInfectious disease specialistsSafety of treatmentNational Psoriasis FoundationBenefits of treatmentMedical boardsOral retinoidsTopical therapyModerate diseaseCase seriesDisease specialistsImmunodeficiency virusTreatment options
2005
The treatment of psoriasis with etanercept.
Strober B. The treatment of psoriasis with etanercept. Seminars In Cutaneous Medicine And Surgery 2005, 24: 28-36. PMID: 15900796, DOI: 10.1016/j.sder.2005.01.003.Peer-Reviewed Original ResearchConceptsTreatment of psoriasisTumor necrosis factor receptorTumor necrosis factor-alpha inhibitorsNecrosis factor-alpha inhibitorsSigns of psoriasisAppropriate patient selectionPathogenesis of psoriasisNecrosis factor receptorEtanercept therapySevere psoriasisTolerability profilePatient selectionRisk ratioTNF-alphaAlpha inhibitorsClinical trialsEtanerceptProinflammatory activityPsoriasisBetter efficacyHigh dosesFactor receptorPatientsSignificant reductionTreatment